Patent Prosecution Overview

Patent prosecution is the process of obtaining a patent through the US Patent and Trademark Office (USPTO), from filing through examination and ultimately to issuance or abandonment: OVERVIEW OF THE PATENT PROSECUTION PROCESS: patent prosecution refers to all interactions between an applicant (or their attorney) and the USPTO; 'ex parte prosecution' (most common) involves the applicant and the USPTO — no third-party participation during examination; 'inter partes' proceedings (IPR, PGR) are different — they involve third parties challenging an issued patent before the PTAB; THE COMPLETE PROSECUTION TIMELINE: (1) DRAFTING PHASE: preparation of the specification (background; summary; detailed description; drawings); preparation of the claims (independent and dependent); oath or declaration (naming the inventors); application data sheet (ADS — identifying inventors, applicant, classification); (2) FILING: application submitted to USPTO via EFS-Web (now Patent Center) or paper; filing receipt issued with serial number; effective FILING DATE secured — critical for prior art purposes; filing fee paid (varies by entity size and claim count); (3) FORMALITIES REVIEW: USPTO reviews for minimum requirements (specification; at least one claim; inventor info); missing elements result in a Notice to File Missing Parts; (4) PUBLICATION: application published at 18 months from earliest claimed priority date; publication creates § 154(d) provisional rights (damages from publication date if infringer had actual notice and patent later issues); applicants can request NON-PUBLICATION within 2.5 months of filing (but only if no foreign filing); (5) DOCKETING AND EXAMINATION: application assigned to an ART UNIT (technology-specific examiner group) and EXAMINER; (6) FIRST OFFICE ACTION (FOA): examiner's first substantive response; typically a rejection (~90% of applications receive at least one rejection); (7) APPLICANT RESPONSE: response to each rejection; (8) SUBSEQUENT OFFICE ACTIONS: typically a second (final) OA after the first response; (9) ALLOWANCE AND ISSUANCE: if claims are allowable, Notice of Allowance (NOA) is issued; issue fee paid within 3 months; patent issues; AVERAGE TOTAL TIME: 24-30 months from filing to issuance.

USPTO examination is the substantive review of whether the claimed invention is patentable: THE EXAMINER'S ROLE: a USPTO patent examiner is a government employee with technical expertise in the relevant art unit; the examiner is responsible for: searching the prior art (patent databases; non-patent literature); evaluating the claims against the prior art; ensuring the specification meets § 112(a) requirements; issuing office actions (rejections and objections); TIMING OF FIRST OFFICE ACTION: the first office action typically issues 16-22 months after the application's filing date; this varies significantly by art unit (some art units have pendency of 3+ years; others less than 12 months); THE MOST COMMON TYPES OF REJECTIONS: (1) § 103 — OBVIOUSNESS: the most common rejection; the examiner identifies two or more prior art references and argues that a POSITA would have combined them to reach the claimed invention; often accompanied by a § 102 rejection as a fallback; (2) § 102 — ANTICIPATION: the examiner finds a SINGLE prior art reference that discloses every limitation of the claim; less common than obviousness because every element must be in one reference; (3) § 101 — PATENT ELIGIBILITY: claims directed to abstract ideas, laws of nature, or natural phenomena; common for software, business method, and diagnostic method claims; Alice/Mayo two-step analysis; (4) § 112(b) — INDEFINITENESS: claim language is not precise enough for a POSITA to determine the scope with reasonable certainty (Nautilus standard); (5) § 112(a) — WRITTEN DESCRIPTION / ENABLEMENT: the specification does not adequately support the breadth of the claimed invention; common for broad genus claims in biotech and chemistry; (6) DOUBLE PATENTING: two related applications claim the same or obvious variants of the same invention; requires terminal disclaimer (for obviousness-type double patenting); NON-FINAL vs. FINAL OFFICE ACTIONS: the FIRST complete examination of all claims is NON-FINAL; the applicant gets a full response with amendments; after the first response, the next OA is typically FINAL; the examiner has discretion to make the second OA non-final if the applicant's first response introduced a NEW issue.

Strategic office action responses can significantly affect the scope, strength, and timing of the resulting patent: GENERAL RESPONSE STRATEGY — THE PRINCIPLE OF MINIMUM NECESSARY CHANGE: minimize amendments that narrow claim scope; argue first, amend as a last resort; every narrowing amendment creates prosecution history estoppel (Festo — limits doctrine of equivalents); TYPES OF RESPONSES: (1) ARGUMENTS ONLY: contest the rejection on legal or factual grounds without amending the claims; advantage: preserves full claim scope + no estoppel; disadvantage: if rejected again, must still respond or file RCE; when to use: when the examiner clearly misread the prior art; when the rejection is legally deficient (insufficient motivation to combine; misapplied claim construction); (2) AMENDMENT + ARGUMENTS: add limitations to distinguish over prior art; minimizes the amendment to only what is necessary; include arguments explaining why even the amended claims are not obvious (not just why they differ from the prior art); (3) EXAMINER INTERVIEW: request a telephonic, video, or in-person interview with the examiner; discuss the rejection and explore allowable subject matter before submitting a formal response; dramatically increases allowance rates when done effectively; prepare SPECIFIC proposed claim language before the interview; RESPONDING TO SPECIFIC REJECTIONS: § 103 OBVIOUSNESS: challenge the motivation to combine (specific references; no specific rationale); challenge the reasonable expectation of success; challenge teaching away by one reference; submit secondary considerations evidence (§ 1.132 declaration: commercial success; unexpected results; long-felt need; failure of others); § 102 ANTICIPATION: identify the specific element missing from the single reference; argue the reference discloses a different context; the reference does not inherently disclose the element; § 101: argue practical application in Prong 2; specific technical improvement to technology; concrete and specific implementation; § 112(a): additional specification support; argue Wands factors; submit § 1.132 expert declaration; DECLARATION PRACTICE (37 C.F.R. § 1.132): expert declarations providing evidence of secondary considerations; inventor declarations establishing unexpected results; technical expert declarations explaining what a POSITA would understand from the specification.

Several critical decision points arise during prosecution that require careful strategic analysis: DECISION POINT 1 — PROVISIONAL vs. NON-PROVISIONAL FILING: FILE PROVISIONAL when: need to establish an early priority date; not ready for full specification; using as a portfolio placeholder; cost savings (no examination fee); CONSTRAINTS: provisional must contain a full written description; must convert within 12 months; provisional does NOT start the examination clock; FILE NON-PROVISIONAL directly when: want to start examination sooner; no foreign filing needed (avoid Paris Convention costs); DECISION POINT 2 — CLAIM SCOPE ON FILING: breadth vs. validity tradeoff; broader claims have more commercial value but are more vulnerable to prior art rejections; draft a range: very broad independent claims + progressively narrower fallback claims; this telescoping strategy preserves options during prosecution; DECISION POINT 3 — RESPONDING TO FIRST REJECTION: argue first (no estoppel); judge: is this examiner persuadable?; is there a simple amendment that overcomes the rejection without sacrificing claim scope?; use examiner interview to explore allowable subject matter; DECISION POINT 4 — NON-PUBLICATION DECISION: if no foreign filing is planned, consider a non-publication request; keeps the application secret until grant; but: application must be abandoned before publication if the applicant later changes their mind; DECISION POINT 5 — AFTER FINAL REJECTION: AFCP 2.0 (no fee; non-broadening amendment); Pre-Appeal Brief Conference; RCE (cost: $900 small; PTA C-delay); notice of appeal (generates PTA if examiner is wrong; but adds 18-24 months); DECISION POINT 6 — ISSUE FEE vs. CONTINUATION: pay issue fee and let the application issue; OR file a continuation BEFORE paying the issue fee to continue prosecution; continuation captures claims the issued patent doesn't cover; strategically file continuation when: competitors have entered the market with products; the issued claims should be supplemented; DECISION POINT 7 — MAINTENANCE FEE DECISIONS: at 3.5, 7.5, and 11.5 years from issuance; evaluate commercial value vs. cost; consider licensing; consider defensive publication if the patent is not being enforced.

Patent term adjustment (PTA) compensates applicants for delays caused by the USPTO during prosecution: BASELINE PATENT TERM: 20 years from the earliest effective non-provisional filing date (35 U.S.C. § 154); term is calculated from FILING DATE, not from issuance; a patent issued after a longer prosecution has FEWER years of remaining term; PTA COMPENSATES FOR THIS: PTA extends the patent term by the number of days attributable to USPTO delays; PTA is calculated by the USPTO and listed on the face of the patent when it issues; THE THREE TYPES OF USPTO DELAY (A, B, C): A-DELAY: the USPTO fails to take a specific action within 14 months of the application filing date (for the first OA); or within 4 months of any applicant response; if the USPTO takes 5 months to issue the first OA after filing, A-delay = 1 month (5 months - 4 months); B-DELAY: if more than 3 years elapse from the effective filing date to the issuance date without an RCE being filed, EVERY DAY BEYOND 3 YEARS is a B-delay day; B-delay typically generates significant PTA in cases with normal prosecution timelines; C-DELAY (APPLICANT DELAY — SUBTRACTS): time attributable to applicant delays REDUCES PTA: any extension of time for responding to an OA; time in RCE prosecution; appeals filed by the applicant that are pending; FDA regulatory review periods (but these are addressed separately under § 156 PTE); THE RCE TRAP: RCE prosecution time is excluded from PTA (C-delay); if you file an RCE 2 years into prosecution and it takes another 12 months, those 12 months are subtracted from PTA; this can result in NEGATIVE PTA contribution from RCE prosecution; CALCULATING PTA IN PRACTICE: PTA = A-delay + B-delay - C-delay (overlapping delays are not double-counted); the USPTO calculates PTA at issuance; applicants can petition to correct the USPTO's PTA calculation within 2 months of patent issuance; IMPORTANCE FOR HIGH-VALUE PATENTS: for pharmaceutical and medical device patents, every day of patent term matters enormously; careful prosecution strategy around RCE, extensions, and appeals can preserve months or years of additional patent term.